Limbic encephalitis associated with inappropriate se-cretion of antidiuretic hormone
A case report and literature review
DOI:
https://doi.org/10.29193/RMU.39.1.10Keywords:
LIMBIC ENCEPHALITIS, HYPONATREMIA, INAPPROPRIATE ADH SYNDROME, DEMENTIAAbstract
Autoimmune limbic encephalitis is a rather unusual neurological condition with subacute progression and neuropsychological symptoms. Currently, acute or maintenance treatment with immunotherapy is targeted depending on the accompanying neural specific antibody and the presence or absence of cancer.
The study presents the case of a 52-year-old woman suffering from autoimmune hypothyroidism, syndrome of inappropriate secretion of anti-diuretic hormone (SIADH) and persistent hyponatremia, with progressive evolution which involved memory loss and faciobrachial dystonic seizures (FBDS). She was timely diagnosed with limbic encephalitis and was treated with intravenous combined corticosteroids and immunoglobulin therapy. Response was good, with minimum neuropsychological.
Recognizing this condition allows for early diagnosis and treatment, what is key to improve the prognosis of these patients.
References
1) Granerod J, Ambrose H, Davies N, Clewley J, Walsh A, Morgan D, et al. Causes of encephalitis and differences in their clinical presenta-tions in England: a multicentre, population-based prospective study. Lancet Infect Dis 2010; 10(12):835-44. doi: 10.1016/S1473-3099(10)70222-X.
2) Ramanathan S, Mohammad S, Brilot F, Dale R. Autoimmune en-cephalitis: recent updates and emerging challenges. J Clin Neurosci 2014; 21(5):722-30. doi: 10.1016/j.jocn.2013.07.017.
3) Kumar R. Understanding and managing acute encephalitis. F1000Res 2020; 9:F1000 Faculty Rev-60. doi: 10.12688/f1000research.20634.1.
4) da Rocha A, Nunes R, Maia AJr, do Amaral L. Recognizing autoim-mune-mediated encephalitis in the differential diagnosis of limbic disorders. AJNR Am J Neuroradiol 2015; 36(12):2196-205. doi: 10.3174/ajnr.A4408.
5) Bien C, Vincent A, Barnett M, Becker A, Blümcke I, Graus F, et al. Immunopathology of autoantibody-associated encephalitides: clues for pathogenesis. Brain 2012; 135(Pt 5):1622-38. doi: 10.1093/brain/aws082.
6) Banks S, Sechi E, Flanagan E. Autoimmune encephalopathies pre-senting as dementia of subacute onset and rapid progression. Ther Adv Neurol Disord 2021; 14:1756286421998906. doi: 10.1177/1756286421998906.
7) Dalmau J, Graus F. Antibody-mediated encephalitis. N Engl J Med 2018; 378(9):840-51. doi: 10.1056/NEJMra1708712.
8) Jammoul A, Li Y, Rae-Grant A. Autoantibody-mediated encephalitis: not just paraneoplastic, not just limbic, and not untreatable. Cleve Clin J Med 2016; 83(1):43-53. doi: 10.3949/ccjm.83a.14112.
9) Graus F, Titulaer M, Balu R, Benseler S, Bien C, Cellucci T, et al. A clinical approach to diagnosis of autoimmune encephalitis. Lancet Neurol 2016; 15(4):391-404. doi: 10.1016/S1474-4422(15)00401-9.
10) Ortega Suero G, Sola-Valls N, Escudero D, Saiz A, Graus F. Anti-Ma and anti-Ma2-associated paraneoplastic neurological syn-dromes. Neurologia (Engl Ed) 2018; 33(1):18-27. doi: 10.1016/j.nrl.2016.05.010.
11) Soler B, Godoy J, Mellado, P. Encefalitis límbica por anticuer-pos anticanales de potasio dependientes de voltaje: caso clínico. Rev Méd Chile 2009; 137(5):675-9. doi: 10.4067/S0034-98872009000500012.
12) Corsellis J, Goldberg G, Norton A. Limbic encephalitis and its association with carcinoma. Brain 1968; 91(3):481-96. doi: 10.1093/brain/91.3.481.
13) Gultekin S, Rosenfeld M, Voltz R, Eichen J, Posner J, Dalmau J. Paraneoplastic limbic encephalitis: neurological symptoms, immu-nological findings and tumour association in 50 patients. Brain 2000; 123(Pt 7):1481-94. doi: 10.1093/brain/123.7.1481.
14) Dalmau J, Lancaster E, Martínez-Hernández E, Rosenfeld M, Balice-Gordon R. Clinical experience and laboratory investigations in patients with anti-NMDAR encephalitis. Lancet Neurol 2011; 10(1):63-74. doi: 10.1016/S1474-4422(10)70253-2.
15) Vincent A, Buckley C, Schott J, Baker I, Dewar B, Detert N, et al. Potassium channel antibody-associated encephalopathy: a po-tentially immunotherapy-responsive form of limbic encephalitis. Brain 2004; 127(Pt 3):701-12. doi: 10.1093/brain/awh077.
16) Shen K, Xu Y, Guan H, Zhong W, Chen M, Zhao J, et al. Paraneoplastic limbic encephalitis associated with lung cancer. Sci Rep 2018; 8(1):6792. doi: 10.1038/s41598-018-25294-y.
17) Moise A, Karakis I, Herlopian A, Dhakar M, Hirsch L, Cotsonis G, et al. Continuous EEG findings in autoimmune encephalitis. J Clin Neurophysiol 2021; 38(2):124-9. doi: 10.1097/WNP.0000000000000654.
18) van Sonderen A, Thijs R, Coenders E, Jiskoot L, Sanchez E, de Bruijn M, et al. Anti-LGI1 encephalitis: Clinical syndrome and long-term follow-up. Neurology 2016; 87(14):1449-56. doi: 10.1212/WNL.0000000000003173.
19) Qiao J, Zhao X, Wang S, Li A, Wang Z, Cao C, et al. Functional and structural brain alterations in encephalitis with LGI1 antibodies. Front Neurosci 2020; 14:304. doi: 10.3389/fnins.2020.00304.
20) Renjen P, Chaudhari D. A review of autoimmune encephalitis. Int J Sci Res 2017; 6(12):286-8.
21) Degnan A, Levy L. Neuroimaging of rapidly progressive de-mentias, part 1: neurodegenerative etiologies. AJNR Am J Neuro-radiol 2014; 35(3):418-23. doi: 10.3174/ajnr.A3454.
22) Wang S, Zhao Y, Wang Q, Guo B, Liu Y, Yan C. Pearls & Oy-sters: limbic encephalitis associated with positive anti-LGI1 and antithyroid antibodies. Neurology 2016; 86(2):e16-8. doi: 10.1212/WNL.0000000000002259.
23) Tamagno G, Celik Y, Simó R, Dihné M, Kimura K, Gelosa G, et al. Encephalopathy associated with autoimmune thyroid disease in patients with Graves’ disease: clinical manifestations, follow-up, and outcomes. BMC Neurol 2010; 10:27. doi: 10.1186/1471-2377-10-27.
24) Luster J, Barasa A, Hoffman W. Rapidly progressive dementia with recurrent seizures and hyponatremia: a case of LGI1 limbic encephalitis. Neurology 2022; 99(23 Suppl 2):S45. Doi: 10.1212/01.wnl.0000903360.38972.63.
25) Wu H, Mei F, Liu L, Zhang L, Hao H, Zhang S. Case Re-port/Case Series: rare case of anti-LGI1 limbic encephalitis with rapidly progressive dementia, psychiatric symptoms, and frequently seizures: a case report. Medicine (Baltimore) 2021; 100(29):e26654. doi: 10.1097/MD.0000000000026654.
26) Li X, Yuan J, Liu L, Hu W. Antibody-LGI 1 autoimmune en-cephalitis manifesting as rapidly progressive dementia and hypo-natremia: a case report and literature review. BMC Neurol 2019; 19(1):19. doi: 10.1186/s12883-019-1251-4.
27) Griffith S, Malpas C, Alpitsis R, O’Brien T, Monif M. The neu-ropsychological spectrum of anti-LGI1 antibody mediated autoim-mune encephalitis. J Neuroimmunol 2020; 345:577271. doi: 10.1016/j.jneuroim.2020.577271.
28) Younger D. Autoimmune encephalitides. World J Neurosci 2017; 7(3):327-61. doi:10.4236/wjns.2017.73027.
29) Chandran, S. Anti LGI1 encephalitis–a retrospective analysis of clinical features and treatment response. Neurology 2021; 96(Suppl 15):e2716.
30) Lai M, Huijbers M, Lancaster E, Graus F, Bataller L, Balice-Gordon R, et al. Investigation of LGI1 as the antigen in limbic encephalitis previously attributed to potassium channels: a case se-ries. Lancet Neurol 2010; 9(8):776-85. doi: 10.1016/S1474-4422(10)70137-X.
31) Head K, Gong S, Joseph S, Wang C, Burkhardt T, Rossi M, et al. Defining the expression pattern of the LGI1 gene in BAC trans-genic mice. Mamm Genome 2007; 18(5):328-37. doi: 10.1007/s00335-007-9024-6.
32) Bien C. Management of autoimmune encephalitis. Curr Opin Neurol 2021; 34(2):166-71. doi: 10.1097/WCO.0000000000000909.
33) Flanagan E, McKeon A, Lennon V, Boeve B, Trenerry M, Tan K, et al. Autoimmune dementia: clinical course and predictors of im-munotherapy response. Mayo Clin Proc 2010; 85(10):881-97. doi: 10.4065/mcp.2010.0326.
34) Lee W, Lee S, Byun J, Sunwoo J, Kim T, Lim J, et al. Rituximab treatment for autoimmune limbic encephalitis in an institutional co-hort. Neurology 2016; 86(18):1683-91. doi: 10.1212/WNL.0000000000002635.
35) Hermetter C, Fazekas F, Hochmeister S. Systematic review: syndromes, early diagnosis, and treatment in autoimmune enceph-alitis. Front Neurol 2018; 9:706. doi: 10.3389/fneur.2018.00706.
36) Deuschl C, Rüber T, Ernst L, Fendler W, Kirchner J, Mönning-hoff C, et al. 18F-FDG-PET/MRI in the diagnostic work-up of limbic encephalitis. PLoS One 2020; 15(1):e0227906. doi: 10.1371/journal.pone.0227906.
37) Gadoth A, Nisnboym M, Alcalay Y, Weinstein T. LGI1 enceph-alitis associated hyponatremia, is it all in the brain? Neurology 2021; 96(Suppl 15):e2256.
38) von Rhein B, Wagner J, Widman G, Malter M, Elger C, Helm-staedter C. Suspected antibody negative autoimmune limbic en-cephalitis: outcome of immunotherapy. Acta Neurol Scand 2017; 135(1):134-41. doi: 10.1111/ane.12575.
2) Ramanathan S, Mohammad S, Brilot F, Dale R. Autoimmune en-cephalitis: recent updates and emerging challenges. J Clin Neurosci 2014; 21(5):722-30. doi: 10.1016/j.jocn.2013.07.017.
3) Kumar R. Understanding and managing acute encephalitis. F1000Res 2020; 9:F1000 Faculty Rev-60. doi: 10.12688/f1000research.20634.1.
4) da Rocha A, Nunes R, Maia AJr, do Amaral L. Recognizing autoim-mune-mediated encephalitis in the differential diagnosis of limbic disorders. AJNR Am J Neuroradiol 2015; 36(12):2196-205. doi: 10.3174/ajnr.A4408.
5) Bien C, Vincent A, Barnett M, Becker A, Blümcke I, Graus F, et al. Immunopathology of autoantibody-associated encephalitides: clues for pathogenesis. Brain 2012; 135(Pt 5):1622-38. doi: 10.1093/brain/aws082.
6) Banks S, Sechi E, Flanagan E. Autoimmune encephalopathies pre-senting as dementia of subacute onset and rapid progression. Ther Adv Neurol Disord 2021; 14:1756286421998906. doi: 10.1177/1756286421998906.
7) Dalmau J, Graus F. Antibody-mediated encephalitis. N Engl J Med 2018; 378(9):840-51. doi: 10.1056/NEJMra1708712.
8) Jammoul A, Li Y, Rae-Grant A. Autoantibody-mediated encephalitis: not just paraneoplastic, not just limbic, and not untreatable. Cleve Clin J Med 2016; 83(1):43-53. doi: 10.3949/ccjm.83a.14112.
9) Graus F, Titulaer M, Balu R, Benseler S, Bien C, Cellucci T, et al. A clinical approach to diagnosis of autoimmune encephalitis. Lancet Neurol 2016; 15(4):391-404. doi: 10.1016/S1474-4422(15)00401-9.
10) Ortega Suero G, Sola-Valls N, Escudero D, Saiz A, Graus F. Anti-Ma and anti-Ma2-associated paraneoplastic neurological syn-dromes. Neurologia (Engl Ed) 2018; 33(1):18-27. doi: 10.1016/j.nrl.2016.05.010.
11) Soler B, Godoy J, Mellado, P. Encefalitis límbica por anticuer-pos anticanales de potasio dependientes de voltaje: caso clínico. Rev Méd Chile 2009; 137(5):675-9. doi: 10.4067/S0034-98872009000500012.
12) Corsellis J, Goldberg G, Norton A. Limbic encephalitis and its association with carcinoma. Brain 1968; 91(3):481-96. doi: 10.1093/brain/91.3.481.
13) Gultekin S, Rosenfeld M, Voltz R, Eichen J, Posner J, Dalmau J. Paraneoplastic limbic encephalitis: neurological symptoms, immu-nological findings and tumour association in 50 patients. Brain 2000; 123(Pt 7):1481-94. doi: 10.1093/brain/123.7.1481.
14) Dalmau J, Lancaster E, Martínez-Hernández E, Rosenfeld M, Balice-Gordon R. Clinical experience and laboratory investigations in patients with anti-NMDAR encephalitis. Lancet Neurol 2011; 10(1):63-74. doi: 10.1016/S1474-4422(10)70253-2.
15) Vincent A, Buckley C, Schott J, Baker I, Dewar B, Detert N, et al. Potassium channel antibody-associated encephalopathy: a po-tentially immunotherapy-responsive form of limbic encephalitis. Brain 2004; 127(Pt 3):701-12. doi: 10.1093/brain/awh077.
16) Shen K, Xu Y, Guan H, Zhong W, Chen M, Zhao J, et al. Paraneoplastic limbic encephalitis associated with lung cancer. Sci Rep 2018; 8(1):6792. doi: 10.1038/s41598-018-25294-y.
17) Moise A, Karakis I, Herlopian A, Dhakar M, Hirsch L, Cotsonis G, et al. Continuous EEG findings in autoimmune encephalitis. J Clin Neurophysiol 2021; 38(2):124-9. doi: 10.1097/WNP.0000000000000654.
18) van Sonderen A, Thijs R, Coenders E, Jiskoot L, Sanchez E, de Bruijn M, et al. Anti-LGI1 encephalitis: Clinical syndrome and long-term follow-up. Neurology 2016; 87(14):1449-56. doi: 10.1212/WNL.0000000000003173.
19) Qiao J, Zhao X, Wang S, Li A, Wang Z, Cao C, et al. Functional and structural brain alterations in encephalitis with LGI1 antibodies. Front Neurosci 2020; 14:304. doi: 10.3389/fnins.2020.00304.
20) Renjen P, Chaudhari D. A review of autoimmune encephalitis. Int J Sci Res 2017; 6(12):286-8.
21) Degnan A, Levy L. Neuroimaging of rapidly progressive de-mentias, part 1: neurodegenerative etiologies. AJNR Am J Neuro-radiol 2014; 35(3):418-23. doi: 10.3174/ajnr.A3454.
22) Wang S, Zhao Y, Wang Q, Guo B, Liu Y, Yan C. Pearls & Oy-sters: limbic encephalitis associated with positive anti-LGI1 and antithyroid antibodies. Neurology 2016; 86(2):e16-8. doi: 10.1212/WNL.0000000000002259.
23) Tamagno G, Celik Y, Simó R, Dihné M, Kimura K, Gelosa G, et al. Encephalopathy associated with autoimmune thyroid disease in patients with Graves’ disease: clinical manifestations, follow-up, and outcomes. BMC Neurol 2010; 10:27. doi: 10.1186/1471-2377-10-27.
24) Luster J, Barasa A, Hoffman W. Rapidly progressive dementia with recurrent seizures and hyponatremia: a case of LGI1 limbic encephalitis. Neurology 2022; 99(23 Suppl 2):S45. Doi: 10.1212/01.wnl.0000903360.38972.63.
25) Wu H, Mei F, Liu L, Zhang L, Hao H, Zhang S. Case Re-port/Case Series: rare case of anti-LGI1 limbic encephalitis with rapidly progressive dementia, psychiatric symptoms, and frequently seizures: a case report. Medicine (Baltimore) 2021; 100(29):e26654. doi: 10.1097/MD.0000000000026654.
26) Li X, Yuan J, Liu L, Hu W. Antibody-LGI 1 autoimmune en-cephalitis manifesting as rapidly progressive dementia and hypo-natremia: a case report and literature review. BMC Neurol 2019; 19(1):19. doi: 10.1186/s12883-019-1251-4.
27) Griffith S, Malpas C, Alpitsis R, O’Brien T, Monif M. The neu-ropsychological spectrum of anti-LGI1 antibody mediated autoim-mune encephalitis. J Neuroimmunol 2020; 345:577271. doi: 10.1016/j.jneuroim.2020.577271.
28) Younger D. Autoimmune encephalitides. World J Neurosci 2017; 7(3):327-61. doi:10.4236/wjns.2017.73027.
29) Chandran, S. Anti LGI1 encephalitis–a retrospective analysis of clinical features and treatment response. Neurology 2021; 96(Suppl 15):e2716.
30) Lai M, Huijbers M, Lancaster E, Graus F, Bataller L, Balice-Gordon R, et al. Investigation of LGI1 as the antigen in limbic encephalitis previously attributed to potassium channels: a case se-ries. Lancet Neurol 2010; 9(8):776-85. doi: 10.1016/S1474-4422(10)70137-X.
31) Head K, Gong S, Joseph S, Wang C, Burkhardt T, Rossi M, et al. Defining the expression pattern of the LGI1 gene in BAC trans-genic mice. Mamm Genome 2007; 18(5):328-37. doi: 10.1007/s00335-007-9024-6.
32) Bien C. Management of autoimmune encephalitis. Curr Opin Neurol 2021; 34(2):166-71. doi: 10.1097/WCO.0000000000000909.
33) Flanagan E, McKeon A, Lennon V, Boeve B, Trenerry M, Tan K, et al. Autoimmune dementia: clinical course and predictors of im-munotherapy response. Mayo Clin Proc 2010; 85(10):881-97. doi: 10.4065/mcp.2010.0326.
34) Lee W, Lee S, Byun J, Sunwoo J, Kim T, Lim J, et al. Rituximab treatment for autoimmune limbic encephalitis in an institutional co-hort. Neurology 2016; 86(18):1683-91. doi: 10.1212/WNL.0000000000002635.
35) Hermetter C, Fazekas F, Hochmeister S. Systematic review: syndromes, early diagnosis, and treatment in autoimmune enceph-alitis. Front Neurol 2018; 9:706. doi: 10.3389/fneur.2018.00706.
36) Deuschl C, Rüber T, Ernst L, Fendler W, Kirchner J, Mönning-hoff C, et al. 18F-FDG-PET/MRI in the diagnostic work-up of limbic encephalitis. PLoS One 2020; 15(1):e0227906. doi: 10.1371/journal.pone.0227906.
37) Gadoth A, Nisnboym M, Alcalay Y, Weinstein T. LGI1 enceph-alitis associated hyponatremia, is it all in the brain? Neurology 2021; 96(Suppl 15):e2256.
38) von Rhein B, Wagner J, Widman G, Malter M, Elger C, Helm-staedter C. Suspected antibody negative autoimmune limbic en-cephalitis: outcome of immunotherapy. Acta Neurol Scand 2017; 135(1):134-41. doi: 10.1111/ane.12575.
Downloads
Published
2023-03-16
How to Cite
1.
Orellano P, Perna Ramos A. Limbic encephalitis associated with inappropriate se-cretion of antidiuretic hormone: A case report and literature review. Rev. Méd. Urug. [Internet]. 2023 Mar. 16 [cited 2024 Nov. 21];39(1):e701. Available from: https://revista.rmu.org.uy/index.php/rmu/article/view/1019
Issue
Section
Clinical Cases
